approval of Eliquis (apixaban) to prevent stroke in A fib will intensify the marketing war among the NEW oral anticoagulants

February 2013

The approval of Eliquis (apixaban) to prevent stroke in A fib will intensify the marketing war among the NEW oral anticoagulants.

Eliquis will join Pradaxa (dabigatran) and Xarelto (rivaroxaban) as alternatives to warfarin for atrial fibrillation.

Keep in mind how the new oral anticoagulants stack up for A fib.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Anticoagulants approval of Eliquis (apixaban) to prevent stroke in A fib will intensify the marketing war among the NEW oral anticoagulants
Influenza An earlier and more severe influenza season will bring more questions about how to prevent and treat flu
HIV & AIDS Stribild (STRY-bild), a new combo for HIV
Diabetes LESS aggressive BP goals in some diabetes patients
Dyslipidemia Niacin will continue to fall out of favour for dyslipidemia
Cardiology Fewer patients will get digoxin for atrial fibrillation
Women's Health Some women will now use tamoxifen for up to 10 years instead of 5 years
Cannabinoids Health Canada will change how patients access medical marijuana
Respiratory & Allergy Patients who suffer from seasonal allergic rhinitis will be able to try SUBLINGUAL Oralair (ORR-ah-lair)
Menopause alternatives to treat menopausal symptoms
Insomnia Sublinox (zolpidem) 5 mg tablets will be hitting your pharmacy shelves along with new dosing changes